HER2 breast cancer treatment decision study
Part of Cancer clinical trials.
This study tests a tool called HER2DX to help doctors choose the best treatment for early stage HER2 positive breast cancer. It may help tailor therapy before or after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have HER2 positive breast cancer confirmed by biopsy.
- Your cancer must be early stage (stage I, II, or III) and not spread to other parts of the body.
- You must be a candidate for treatment before surgery (neoadjuvant) or after surgery (adjuvant), along with surgery and possibly radiation.
- You must be willing to sign a consent form agreeing to the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
This trial looks back at premenopausal women with early-stage, hormone-positive, HER2-negative breast cancer who had surgery and an Oncotype DX test, to see how different treatments affected their outcomes. If you fit this group, your past medical records could help researchers learn more about the best treatments.
This trial tests whether a new test (HER2DX) can help doctors choose the best treatment combination for HER2-positive breast cancer before surgery. It's for people whose cancer hasn't spread and who haven't started therapy yet.
This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
Hear when a new Breast Cancer Early Stage Breast Cancer (Stage 1-3) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.